PLPL (Plandai Biotechnology) Debt-to-EBITDA : -0.00 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Plandai Biotechnology Debt-to-EBITDA?

Plandai Biotechnology PLPL -90.00% Debt-to-EBITDA is -0.00 as of Jun. 2023.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Plandai Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.05 Mil. Plandai Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Plandai Biotechnology's annualized EBITDA for the quarter that ended in Jun. 2023 was $-19.77 Mil. Plandai Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Plandai Biotechnology's Debt-to-EBITDA or its related term are showing as below:

PLPL's Debt-to-EBITDA is not ranked *
in the Business Services industry.
Industry Median: 1.66
* Ranked among companies with meaningful Debt-to-EBITDA only.

Plandai Biotechnology  (OTCPK:PLPL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Plandai Biotechnology Debt-to-EBITDA Related Terms

Plandai Biotechnology Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Plandai Biotechnology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plandai Biotechnology Debt-to-EBITDA Chart

Plandai Biotechnology Annual Data
Trend Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -1.66 -5.87 0.02 -0.00

Plandai Biotechnology Semi-Annual Data
Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -1.66 -5.87 0.02 -0.00

PLPL vs CRGH, TCRI, MAYX: Debt-to-EBITDA Comparison

For the Specialty Business Services subindustry, Plandai Biotechnology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plandai Biotechnology Debt-to-EBITDA vs Business Services Industry

For the Business Services industry and Industrials sector, Plandai Biotechnology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Plandai Biotechnology's Debt-to-EBITDA falls into.


Plandai Biotechnology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Plandai Biotechnology's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.05 + 0) / -19.773
=-0.00

Plandai Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.05 + 0) / -19.773
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Jun. 2023) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.00 mean?
Plandai Biotechnology (PLPL) has a Debt-to-EBITDA of -0.00 as of Jun. 2023. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Plandai Biotechnology.
Is Plandai Biotechnology's Debt-to-EBITDA too high?
Plandai Biotechnology's current Debt-to-EBITDA is -0.00.
How does Plandai Biotechnology's Debt-to-EBITDA compare to CRGH and TCRI?
Plandai Biotechnology's Debt-to-EBITDA of -0.00 can be compared against companies in the Business Services industry. The industry median Debt-to-EBITDA is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Business Services company?
The median Debt-to-EBITDA among Business Services companies is 1.66, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Plandai Biotechnology. For the Business Services industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plandai Biotechnology's current Debt-to-EBITDA is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plandai Biotechnology stock overvalued right now?
Plandai Biotechnology (PLPL) has a current Debt-to-EBITDA of -0.00. The current Debt-to-EBITDA is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Plandai Biotechnology (PLPL), the current Debt-to-EBITDA is -0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plandai Biotechnology Business Description

Address Xinyi Road, Sector 5, No. 7, 57th Floor - 1, Xinyi District, Taipei, TWN, 330
Plandai Biotechnology Inc is engaged in catering and catering management operations in Taiwan.